Summit Therapeutics PLC | Mutual Funds
Mutual Funds that own Summit Therapeutics PLC
Marlborough Special Situations Fund
3,069,162
3.74%
1,173,329
0.07%
03/29/2018
Marlborough UK Micro Cap Growth Fund
1,959,655
2.39%
460,814
0.06%
03/29/2018
Polar Capital Funds Plc - Biotechnology Fund
1,500,000
1.83%
0
0.15%
07/31/2018
Baillie Gifford Overseas Growth Fund - Global Discovery Fund
915,138
1.11%
0
0.07%
04/30/2018
Jupiter UK Smaller Companies Fund
750,000
0.91%
0
0.09%
02/28/2018
Polar Capital Global Healthcare Growth & Income Trust Plc
744,933
0.91%
-1,240
0.08%
09/30/2017
Edinburgh Worldwide Investment Trust Plc
709,940
0.86%
0
0.06%
10/31/2017
Artemis Alpha Trust Plc
483,871
0.59%
100,773
0.11%
10/31/2017
295,704
0.36%
117,463
0.06%
03/29/2018
| Address |
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
|
|
Employees
|
- |
| Website |
http://summitplc.com |
| Updated |
07/08/2019 |
| Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom. |
